A coalition of 43 state attorneys general has filed a sweeping lawsuit accusing pharmaceutical giant Novartis and its former subsidiary Sandoz of orchestrating a massive bid-rigging scheme for 31 generic drugs, calling it one of the most brazen conspiracies ever uncovered in the industry.
Swiss pharmaceutical giant Novartis forecasts a low single-digit percentage decline in its 2026 operating profit, citing intensifying pressure from generic rivals to key drugs like Entresto.
The Swiss pharma giant reported robust 2025 results, hitting a key profitability goal early. While facing near-term pressure from U.S. generic competition, CEO Vas Narasimhan outlined a strategy anchored by a portfolio of growth brands and a promising late-stage pipeline.
Siemens Healthineers reported a resilient start to fiscal 2026, with strong performance in its imaging and precision therapy divisions offsetting a significant downturn in its diagnostics business in China, prompting a strategic reassessment of its operations in the key Asian market.
Shares of the Danish pharmaceutical giant tumbled over 14% as management's forecast of a sales and profit decline in 2026 shifted investor focus from blockbuster results to looming pricing battles and competitive threats in the crucial U.S. market.
As U.S. markets rebound, Vanguard's VYMI ETF has delivered a 41% surge by tapping into high-yield international stocks, offering investors a potent mix of income and geographic diversification.
A detailed analysis of Alcon Inc. (ALC) highlights the company's market leadership, margin expansion potential, and the upcoming catalyst of its UNITY surgical system, presenting a compelling bull case for the eye care specialist.
Sanofi reports a pivotal Phase 3 win for its investigational therapy venglustat in a rare neurological disorder, alongside positive EU regulatory news for Rezurock and progress for amlitelimab, signaling a strategic shift toward high-value specialty medicines.
BeOne Medicines (NasdaqGS: ONC) has significantly expanded its strategic partnership with systems biology firm InSysBio. The deepened collaboration aims to leverage advanced mechanistic modeling to de-risk clinical trial design, with a particular focus on optimizing dosing and preempting safety challenges like cytokine release syndrome in oncology studies.
Sanofi announces promising late-stage results for its immunology candidate amlitelimab and expands into genetic therapies via an investment in Sensorion, signaling a strategic push into high-value therapeutic areas.
